Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield ... ( SOUTH SAN FRANCISCO Calif. June 5...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management

Date:6/5/2008

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced earlier today that it has received a $150.0 million funding commitment from Deerfield Management. The arrangement will be discussed by Exelixis management in a live conference call at 5:00 a.m. PT/8:00 a.m. ET today, Thursday, June 5. To listen to a webcast of the discussion, visit the Event Calendar page under Investors at http://www.exelixis.com.

A replay of the conference call will be available until 7:00 a.m. PT/10:00 a.m. ET on July 5, 2008. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 33494166.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:11/24/2009)...YKJAVIK,Iceland,November24/PRNewswire-FirstCall/--...heapprovalofallofits,"firstday"motionsbytheU.S.Ban...cyCourt").deCODElastweekfiledavoluntarypetitionfor...dewiththe,BankruptcyCourt. , Theordersissuedb...rateitsbusinessduringtheChapter11proceedings.Inpar...

(Date:11/24/2009)...ANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyann...SFDA)hasapprovedthe,investigationalnewdrugapplicat...tiveinsulinformulationtotreatdiabetes.ThisIND,appr...tudy. , Diabetesisadisordercharacteristicofhi...fdiabetesoftenresultinseveremicro-and,macro-vascul...

(Date:11/24/2009)...imaryefficacyendpointhasbeenmetforpatientswithadva...EBECCITY,Nov.24/PRNewswire-FirstCall/-AEternaZenta...albiopharmaceuticalcompanyfocusedonendocrinetherap...maPhase2studywithitstargetedcytotoxicpeptideconjug...dorrecurrentendometrialcancer.Inapersonalizedhealt...

(Date:11/24/2009)...NDIEGO,Nov.24,2009/PRNewswire-FirstCall/--ArenaPha...atthecompanyisscheduledtopresentatthePiperJaffray2...30a.m.EasternTime(8:30a.m.PacificTime)attheNewYork...t andChiefExecutiveOfficer,isscheduledtoprovideano...tanddiscoveryprograms. ,, Aliveaudiowebcastofth...

Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2 deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3 Biolaxy Secures IND Approval for Oral Insulin 2 AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2 AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3 AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4 Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2

[0] deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court [0] Biolaxy Secures IND Approval for Oral Insulin [0] AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer [0] Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference

...FRANCISCO, Calif., May 14 VaxGen,Inc. (OTC Bullet...y,provided guidance on its expected monthly cash e...g undertaken on April 9, 2008. VaxGen expects that...rd are unlikely to exceed,$1 million, made up of t... Company,s real estate and facility, estimated at ...

... May 14 Sigma-Aldrich (Nasdaq:,SIAL) announced to...nancial,Officer Michael R. Hogan will retire at a ...ed 55 in April, had notified the Company early thi...essor could be identified,and successfully transit...ify a successor from a pool of internal and extern...

...mer,s Study Group Outlines a National Plan, WASHI...ustice Sandra Day O,Connor and Former Speaker of t...ecial hearing of the U.S. Senate,Special Committee...hl,(D-WI) specifically to hear updates on the figh...Connor,s first public statement about her,commitme...

Other Biology Technology:Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance 2 Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance 3 Sigma-Aldrich (Nasdaq: SIAL) CAO & CFO Hogan Plans to Retire; Search for Successor Underway 2 Retired Supreme Court Justice Sandra Day O'Connor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimer's Disease 2 Retired Supreme Court Justice Sandra Day O'Connor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimer's Disease 3

Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance Sigma-Aldrich (Nasdaq: SIAL) CAO & CFO Hogan Plans to Retire; Search for Successor Underway Retired Supreme Court Justice Sandra Day O'Connor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimer's Disease

(Date:11/24/2009)... may help gut bacteria bind to the gastrointestina...oducers to identify strains that are likely to be ...interact with cells lining the gut to have a benef...e gut they are more likely to stick around long en...ge from the Institute of Food Research. IFR is an...

(Date:11/24/2009)...l Toxicology (ACMT) have signed an agreement to co...dical Toxicology (JMT), the official journal of t...ly published by the University of Pennsylvania Pre...nternational, peer-reviewed journal, is dedicated ...oxicology. The quarterly journal focuses on the d...

(Date:11/24/2009)...debate. A high-profile study a few years ago sugge...on from trees and leaves, evidence for a very clos...ems. , But new research from the University of W...ae provide a much richer diet for fish and other a...week in the Proceedings of the National Academy o...

Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2 Springer and the American College of Medical Toxicology to work together 2 Fish food fight: Fish don't eat trees after all, says new study 2 Fish food fight: Fish don't eat trees after all, says new study 3 Omega 3s Benefit Heart Attack Survivors Healthy Adults Mothers and Infants 51086 1 Omega 3s Benefit Heart Attack Survivors Healthy Adults Mothers and Infants 51086 2 March of Dimes Names Two New Trustees 51084 1 March of Dimes Names Two New Trustees 51084 2 Forsyth Medical Center participating in Avastin trial for new glioblastoma patients 51082 1 Forsyth Medical Center participating in Avastin trial for new glioblastoma patients 51082 2

[1] A sticky solution for identifying effective probiotics [1] Springer and the American College of Medical Toxicology to work together [0] Fish food fight: Fish don't eat trees after all, says new study

... gene responsible for the production of a protein ... treating pancreatic cancer, suggests research pub...is the fifth leading cause of cancer deaths in the...eat. Only 3% of affected patients are still alive ...as remained static for the past three decades. , ...

...ale is a founding member of the Genome-Wide RNAi G... biomedical research centers formed to speed scien... the entire human genome. The initiative is sponso...t complete human genome siRNA library, or compilat...es. The library is designed to determine when indi...

...accines have helped eradicate and tame some of his...ny more diseases out there that vaccines can help ...t to unlock the future promise of vaccines against...a new report by the American Academy of Microbiolo...ase has been profound. Many diseases that formerl...

Other Biology News:Gene therapy potential for treatment of pancreatic cancer 2 Yale participates in global human genome initiative 2 Report focuses on challenges to unlocking future promise of vaccines 2

Gene therapy potential for treatment of pancreatic cancer Yale participates in global human genome initiative Report focuses on challenges to unlocking future promise of vaccines

...system combines world-class performance hardware, ...ftware, Agilents world-renowned support and column...lies--a combination that lets you reach uncompromi...sed on dependable data. The Agilent 6820 GC system...

7890A GC from Agilent Technologies

RF-5301 Fluorescence Spectrophotometer from Shimadzu

Kit for BASE20/50 dual control unit KIT50EHTD from Wave Biotech now part of GE Healthcare

Biology Products:

6820 GC from Agilent Technologies 7890A GC from Agilent Technologies RF-5301 Fluorescence Spectrophotometer from Shimadzu Kit for BASE20/50 dual control unit KIT50EHTD from Wave Biotech now part of GE Healthcare

Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield ...( SOUTH SAN FRANCISCO Calif. June 5...)